# Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

> **NCT02008396** · PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Social Anxiety in Autistic Adults

## Interventions

- **DRUG:** Placebo
- **DRUG:** Midomafetamine HCl
- **BEHAVIORAL:** Therapy

## Key facts

- **NCT ID:** NCT02008396
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-11
- **Primary completion:** 2017-04-28
- **Final completion:** 2017-04-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008396, "Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02008396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*